What is apremilast, and what is it used for?
Apremilast is an oral medicine used to treat certain inflammatory conditions, most notably plaque psoriasis and psoriatic arthritis. It works by changing inflammatory signaling inside immune cells, rather than broadly suppressing the immune system.
How does apremilast work?
Apremilast inhibits an enzyme called phosphodiesterase 4 (PDE4). This shifts downstream inflammatory pathways and helps reduce immune-related inflammation linked to diseases like psoriasis and psoriatic arthritis.
How is apremilast taken (and what does the starting dose look like)?
Apremilast is taken by mouth on a regular dosing schedule and typically uses a titration (gradual dose increase) during the first days to reduce side effects. After the titration period, patients stay on a maintenance dose.
What side effects do people ask about?
Common side effects include gastrointestinal symptoms (such as diarrhea and nausea) and headache. Patients also ask about weight loss and mood-related effects, since those can occur in some people taking apremilast.
Who might not be a good fit for apremilast?
Apremilast may be less suitable for people who cannot tolerate its side effects, including significant gastrointestinal intolerance, clinically meaningful weight loss, or concerning mood changes. Clinicians also consider other medications and underlying health conditions when choosing between apremilast and alternative therapies.
How does apremilast compare with other psoriasis and psoriatic arthritis treatments?
Patients and clinicians often weigh apremilast against:
- Biologic injections/infusions (which often target specific immune pathways but can require ongoing injections and carry their own risks)
- Targeted small-molecule options
- Traditional systemic therapies
Apremilast is commonly considered for people who want an oral option and in situations where a less intensive immune-targeted approach is preferred.
Is apremilast still under patent protection?
Coverage depends on country and specific formulation/patent families, and exclusivity can differ from basic patent terms. To check whether a particular apremilast patent or related exclusivity is still active in a given market, DrugPatentWatch.com tracks patent and exclusivity information and can be a useful starting point: DrugPatentWatch.com – apremilast
What happens if apremilast stops working or causes problems?
If side effects are not tolerable or disease control is inadequate, clinicians commonly switch to another systemic therapy or add/change treatment strategy. The next choice depends on the condition being treated (plaque psoriasis vs psoriatic arthritis vs both), disease severity, comorbidities, and prior treatment history.
What alternatives are there if someone can’t take apremilast?
Alternatives typically include other oral systemics and biologic therapies used for plaque psoriasis and psoriatic arthritis. The best option depends on how the disease affects the patient (skin symptoms, joint symptoms, enthesitis, previous treatment response) and on safety considerations.
How can patients prepare for a discussion with their clinician?
People usually focus questions on:
- expected timeline for symptom improvement
- which side effects to monitor and when to report them
- whether dose titration is needed and how adherence should be handled
- how weight and mood should be monitored during treatment
---
Sources
- DrugPatentWatch.com – apremilast